Mammalian target of rapamycin (mTOR; FRAP; RAFT1); phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1); tumor protein p53 (TP53; p53) BriefCommunication Pages: 479 - 479
Hyaluronan; tumor necrosis factor, α-induced protein 6 (TNFAIP6; TSG6); yeast cytosine deaminase (FCY1; CD) BriefCommunication Pages: 483 - 483
Integrin αvβ3; integrin αvβ5; VEGF; VEGF receptor 2 (VEGFR2; KDR/FLK-1) BriefCommunication Pages: 484 - 484
Mitogen-activated protein kinase 14 (MAPK14; p38); protein kinase B (PKB; Akt) BriefCommunication Pages: 490 - 490
Transient receptor potential cation channel, subfamily C, member 3 (TRPC3) BriefCommunication Pages: 491 - 491
Phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1) BriefCommunication Pages: 496 - 496
Purinergic receptor P2X ligand-gated ion channel 4 (P2RX4); mitogen-activated protein kinase 14 (MAPK14; p38); brain-derived neurotrophic factor (BDNF) BriefCommunication Pages: 502 - 502
Mammalian target of rapamycin (mTOR; FRAP; RAFT1); cAMP responsive element binding protein 1 (CREB1; CREB); granulocyte colony–stimulating factor receptor (CD114); receptor for advanced glycation endproducts (RAGE); ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; CD39); chemokine (C-X-C motif) receptor 4 (CXCR4; NPY3R) BriefCommunication Pages: 508 - 508
Amphiphilic peptide aggregates for hydrophobic drug delivery or hemostasis BriefCommunication Pages: 511 - 511
Autoregulatory brain-derived neurotrophic factor (BDNF) vector for the treatment of obesity and type 2 diabetes BriefCommunication Pages: 512 - 512
Combination, nanoemulsion formulation of paclitaxel and curcumin for drug-resistant tumors BriefCommunication Pages: 513 - 513
Generating of insulin-producing β-cells from human embryonic stem cells using a small molecule BriefCommunication Pages: 514 - 514
Cholecystokinin receptor–selective labeling for in vivo tumor targeting BriefCommunication Pages: 516 - 516